Lucie Raskin: Comparing VTE Risk in Hormonal Contraceptives at NTHC 2026
Lucie Raskin, PhD student at University of Namur, shared on LinkedIn:
”Glad to have presented at NTHC 2026 (Namur Thrombosis and Hemostasis Center)!
I had the opportunity to share our work on a Network Meta-Analysis (NMA) assessing the risk of venous thromboembolism (VTE) associated with hormonal contraceptives (HCs).
This analysis allows us, within a single model, to compare the full range of HCs and to classify VTE risk according to the type of contraceptive.
By integrating all available evidence, this work provides a comprehensive overview that complements biological data and real-world pharmacovigilance findings.
Altogether, the evidence consistently suggests that natural estrogens may represent a safer option compared to EE-based COCs with respect to VTE risk.
I would like to thank my supervisors Jonathan Douxfils and Charlotte Beaudart, as well as the Research Unit in Clinical Pharmacology and Toxicology (URPC) team for their support.”
Stay updated with Hemostasis Today.
-
Apr 10, 2026, 17:39Diverse Voices But Shared Mission – Day 1 of EHC Youth Leadership Workshop
-
Apr 10, 2026, 17:30Make Your Mark at the World Stroke Congress 2026 – World Stroke Organization
-
Apr 10, 2026, 17:23Sofie Abels: Implications for Targeted Screening for Thrombophilia in Young Stroke Patients
-
Apr 10, 2026, 17:08Armghan Ans: 3 Questions Worth Sitting with If You Work in Stroke AI
-
Apr 10, 2026, 17:03William Wallace: Vitamin C Is More Than ”Immune Support”
-
Apr 10, 2026, 16:58Wolfgang Miesbach: Greater Symptom Burden in Women with Bleeding Disorders – Insights from Irish Data
-
Apr 10, 2026, 16:50Leonardo Roever: Non-Pharmacological Approaches Lead in PSCI Treatment
-
Apr 10, 2026, 16:36José Luis Ferreiro: After Stent Treatment in Heart Attack Patients How to Balance Bleeding and Clotting Risk
-
Apr 10, 2026, 15:54Niccolò Bitto: Answers to Some of the Most Frequently Asked Questions on Gene Therapy for Hemophilia